Selected outcome
a full approval or an accelerated approval
90%
a full approval or an accelerated approval · 90%
Stored quote · checking the venue
- Scheduled end
- Dec 31, 2026 ET
- Resolution source
- AppliedXL (opens in a new tab)
Price
a full approval or an accelerated approval
Loading price history.
Markets
- a full approval or an accelerated approval
What will the FDA's decision be on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026?
90%
Open · ~$0 24h · ~$3,690 vol
Bid 86¢ · Ask 93¢
Event statistics
How this resolves
One winner.
- Scheduled end
- Dec 31, 2026 ET
- Resolution source
- Trading
- Closed
- In review
- Resolved
Rules text
If the FDA's decision on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes.